4AB0 Stock Overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
AbbVie Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.30 |
| 52 Week High | US$18.90 |
| 52 Week Low | US$12.70 |
| Beta | 0.56 |
| 1 Month Change | -4.38% |
| 3 Month Change | -8.93% |
| 1 Year Change | 5.15% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -4.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4AB0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -9.5% | -1.5% | 1.9% |
| 1Y | 5.2% | -23.6% | 4.6% |
Return vs Industry: 4AB0 exceeded the German Biotechs industry which returned -21.9% over the past year.
Return vs Market: 4AB0 matched the German Market which returned 4.2% over the past year.
Price Volatility
| 4AB0 volatility | |
|---|---|
| 4AB0 Average Weekly Movement | 6.1% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4AB0 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4AB0's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 50,000 | Rick Gonzalez | www.abbvie.com |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.
AbbVie Inc. Fundamentals Summary
| 4AB0 fundamental statistics | |
|---|---|
| Market cap | €267.15b |
| Earnings (TTM) | €5.54b |
| Revenue (TTM) | €50.63b |
47.6x
P/E Ratio5.2x
P/S RatioIs 4AB0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4AB0 income statement (TTM) | |
|---|---|
| Revenue | US$54.40b |
| Cost of Revenue | US$16.85b |
| Gross Profit | US$37.56b |
| Other Expenses | US$31.60b |
| Earnings | US$5.95b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.37 |
| Gross Margin | 69.03% |
| Net Profit Margin | 10.94% |
| Debt/Equity Ratio | 924.1% |
How did 4AB0 perform over the long term?
See historical performance and comparison